Qiagen (QGEN) AI Stock Analysis

Compare

399 Followers

Top Page

Qiagen

(NYSE:QGEN)

Rating:70Outperform

Price Target:

$47.00

▲(4.14%Upside)

Qiagen's overall stock score of 70 reflects its solid financial performance and positive earnings call results, which indicate strong operational execution and strategic initiatives. However, the high P/E ratio suggests potential overvaluation, and technical analysis shows only moderate positive momentum. These factors balance out to a moderate yet promising outlook for the stock.

Positive Factors

Revenue Growth

The management team has been effective in managing continued revenue growth and improving profitability despite challenges in the sector.

Strategic Acquisitions

The acquisition of Genoox enhances Qiagen's clinical offering for small and mid-sized labs by unlocking cloud-based AI functionality.

Negative Factors

Growth Uncertainty

There is a need for greater confidence in the durability of top-line growth in the latter half of 2025 and into 2026 before considering an upgrade in stock rating.

Segment Challenges

Core growth in the genomics and NGS segment declined and was below expectations, reflecting challenges in some areas.

Qiagen (QGEN) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$9.77B

Dividend YieldN/A

Average Volume (3M)1.36M

Price to Earnings (P/E)108.1

Beta (1Y)0.74

Revenue Growth3.31%

EPS GrowthN/A

CountryUS

Employees5,700

SectorHealthcare

Sector Strength42

IndustryMedical - Diagnostics & Research

Share Statistics

EPS (TTM)0.55

Shares Outstanding216,556,000

10 Day Avg. Volume1,407,654

30 Day Avg. Volume1,362,858

Financial Highlights & Ratios

PEG Ratio6.30

Price to Book (P/B)2.73

Price to Sales (P/S)0.00

P/FCF Ratio18.32

Enterprise Value/Market Cap1.02

Enterprise Value/Revenue1.27

Enterprise Value/Gross Profit9.97

Enterprise Value/Ebitda7.06

Forecast

1Y Price Target

$48.89

Price Target Upside8.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering14

Qiagen Business Overview & Revenue Model

Company DescriptionQiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. Operating in the life sciences and molecular diagnostics sectors, Qiagen offers a comprehensive portfolio of products and services, including sample technologies, assay technologies, bioinformatics, and automation systems. These products are utilized in academic research, pharmaceutical and biotechnology industries, forensics, and clinical diagnostics to advance scientific research and improve patient outcomes.

How the Company Makes MoneyQiagen generates revenue through the sale of its diverse range of products and services designed to automate and streamline the process of extracting, analyzing, and interpreting molecular information. Its key revenue streams include: 1) Consumables and related products, comprising kits and reagents used in sample preparation and molecular testing. 2) Instruments, which include automation systems for sample processing and analysis. 3) Bioinformatics solutions, providing software and services for data interpretation and analysis. Additionally, Qiagen benefits from strategic partnerships and collaborations with academic institutions, pharmaceutical companies, and clinical laboratories, which enhance its market reach and drive sales growth. The company's focus on innovation and expanding its product offerings in high-demand areas, such as oncology and infectious disease testing, also significantly contributes to its earnings.

Qiagen Earnings Call Summary

Earnings Call Date:May 07, 2025

(Q1-2025)

% Change Since: 5.86%|

Next Earnings Date:Aug 12, 2025

Earnings Call Sentiment Positive

Qiagen delivered a strong start to 2025, exceeding expectations for net sales and earnings. Key product lines showed robust growth, and profitability improved significantly. While challenges remain in the China market and cautious customer spending, the company reaffirmed its full-year outlook and expanded shareholder return options, indicating confidence in its strategy and execution.

Q1-2025 Updates

Positive Updates

Exceeded Q1 2025 Outlook

Qiagen delivered net sales of $483 million, representing a 7% increase at constant exchange rates (CER) compared to Q1 2024. Adjusted diluted earnings per share were $0.50, exceeding the outlook for at least $0.50.

Strong Performance of Key Products

QIAstat achieved double-digit sales growth, QuantiFERON tuberculosis test delivered another strong quarter of double-digit sales growth, and QIAcuity digital PCR platform continued to build momentum in high-growth fields.

Increased Profitability

Adjusted operating income margin rose to 29.8% of sales, up more than four percentage points from Q1 2024, driven by a favorable shift towards consumables and bioinformatics solutions.

Reaffirmed Full Year 2025 Outlook

Qiagen expects around 4% sales growth at CER, with an upgraded target for adjusted earnings per share of about $2.35, up $0.07 from the initial outlook for the year.

Expansion of Shareholder Returns

Introduction of an annual cash dividend and proposal for a synthetic share repurchase of up to $500 million for consideration over an 18-month period.

Negative Updates

Challenges in China

Ongoing weak trends in China, which represents about 3% to 4% of total sales, with a high teens CER decline compared to Q1 2024.

Decline in Genomics and NGS Sales

Sales in genomics and next-generation sequencing were down 2% at CER compared to Q1 2024, reflecting lower demand for some NGS consumables and services.

Cautious Customer Spending

Continued cautious environment on spending, especially for capital sales, and discussions around research funding in different countries.

Company Guidance

In the Q1 2025 earnings call, Qiagen reported exceeding their outlook with net sales of $483 million, reflecting a 7% increase at constant exchange rates (CER) compared to Q1 2024. Adjusted diluted earnings per share were $0.50 at CER, surpassing the expected minimum of $0.50. The company reaffirmed its full-year 2025 outlook, projecting around 4% sales growth at CER, and upgraded its adjusted earnings per share target to approximately $2.35 at CER, up $0.07 from the initial guidance. Key growth drivers included QIAstat's double-digit sales increase due to new panel launches, QuantiFERON's strong performance with double-digit sales growth, and the momentum in QIAcuity's digital PCR platform. Qiagen also highlighted its strategic initiatives, including the introduction of a cash dividend and a proposed $500 million synthetic share repurchase, as part of its goal to return at least $1 billion to shareholders by 2028.

Qiagen Financial Statement Overview

Summary

Qiagen demonstrates stable financial health with strong cash flow management and a balanced capital structure. While revenue and profit margins face industry pressures, the company's operational efficiency and sound balance sheet provide a firm foundation for future growth. Continued focus on improving profitability and maintaining cash flow strength will be key to enhancing financial performance.

Income Statement

Positive

Qiagen's TTM revenue of $2.00 billion is slightly higher than the previous annual revenue of $1.98 billion, indicating modest growth. The gross profit margin is 50.0%, showing solid profitability, although it's a decline from past years. The net profit margin stands at 4.7%, which is relatively low but consistent with industry standards in challenging periods. EBIT and EBITDA margins are 5.9% and 18.6%, respectively, suggesting stable operational efficiency despite fluctuations in EBIT over recent years.

Balance Sheet

Positive

The debt-to-equity ratio is 0.41, indicating a solid capital structure with manageable debt levels. Return on Equity (ROE) is a modest 2.7%, reflecting challenges in generating strong returns on equity, partially due to reduced profitability. The equity ratio is a healthy 61.5%, showcasing a strong reliance on equity financing and solid asset backing, which bolsters financial stability.

Cash Flow

Positive

The TTM operating cash flow to net income ratio is robust at 7.26, indicating efficient cash conversion from profits. Free cash flow remains strong at $503 million, with a free cash flow to net income ratio of 5.37, highlighting effective cash management and investment capacity. Free cash flow growth is steady, reinforcing cash flow resilience even as net income fluctuates.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
2.00B	1.98B	1.97B	2.14B	2.25B	1.87B
	Gross Profit
1.00B	1.32B	1.22B	1.38B	1.45B	1.23B
	EBIT
118.11M	97.71M	445.25M	531.46M	630.08M	554.90M
	EBITDA
372.10M	368.26M	688.55M	779.36M	895.24M	715.80M
	Net Income Common Stockholders
93.68M	83.59M	341.30M	423.21M	512.60M	73.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
963.45M	1.15B	1.06B	1.42B	1.07B	714.25M
	Total Assets
5.55B	5.69B	6.12B	6.29B	6.15B	5.97B
	Total Debt
1.41B	1.42B	1.61B	1.86B	1.94B	2.03B
	Net Debt
769.58M	752.33M	943.04M	1.13B	1.06B	1.43B
	Total Liabilities
2.14B	2.12B	2.31B	2.82B	3.05B	3.49B
	Stockholders Equity
3.41B	3.57B	3.81B	3.47B	3.10B	2.48B
Cash Flow		Free Cash Flow
503.07M	506.38M	296.65M	565.93M	432.47M	188.03M
	Operating Cash Flow
680.21M	673.55M	459.45M	715.26M	639.00M	492.27M
	Investing Cash Flow
-135.58M	-249.23M	-87.66M	-726.76M	-202.43M	-453.29M
	Financing Cash Flow
-417.51M	-422.90M	-433.83M	-125.80M	-150.37M	-74.32M

Qiagen Technical Analysis

Technical Analysis Sentiment

Positive

Last Price45.13

Price Trends

50DMA

41.62

Positive

100DMA

41.76

Positive

200DMA

43.01

Positive

Market Momentum

MACD

0.72

Negative

RSI

66.00

Neutral

STOCH

95.20

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Positive. The current price of 45.13 is above the 20-day moving average (MA) of 42.82, above the 50-day MA of 41.62, and above the 200-day MA of 43.01, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 66.00 is Neutral, neither overbought nor oversold. The STOCH value of 95.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QGEN.

Qiagen Risk Analysis

Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Qiagen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (53)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	79 Outperform	$19.35B	21.91	13.35%	1.76%	9.38%	6.43%
QGEN	70 Outperform	$9.77B	108.12	2.67%	―	3.31%	―
NTRA	67 Neutral	$21.54B	―	-18.66%	―	51.50%	53.23%
RVTY	65 Neutral	$10.66B	35.75	3.82%	0.31%	1.62%	78.53%
EXAS	61 Neutral	$10.87B	―	-36.89%	―	11.57%	-315.25%
Sector *	53 Neutral	$5.22B	3.32	-45.04%	2.83%	16.81%	-0.27%
ILMN	52 Neutral	$13.02B	―	-23.82%	―	-3.47%	25.55%

* Healthcare Sector Average

Performance Comparison

QGEN

Qiagen

45.13

1.14

2.59%

EXAS

Exact Sciences

56.28

11.46

25.57%

ILMN

Illumina

82.24

-18.22

-18.14%

RVTY

Revvity

90.42

-18.10

-16.68%

DGX

Quest Diagnostics

173.34

35.03

25.33%

NTRA

Natera

157.73

49.42

45.63%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.